Developer docs
API playgroundTry for free, no card

Search company profiles

Kine Sciences

Full company profile

uuid000bzgr

Namestring
Kine Sciences
Legal namestring
주식회사 카인사이언스 (Kine Sciences Co., Ltd.)
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Kine Sciences (카인사이언스) is a clinical-stage Korean biopharmaceutical company headquartered in Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea, that develops ultra-peptide medicines targeting chronic immune and neuroinflammatory diseases. The company operates two R&D divisions: the Immune Disease Division, which develops regulatory T-cell (Treg) activating peptides that restore immune homeostasis by modulating Treg, Th2, Th17, and NK cell activity, and the Central Research Institute (CRI), which develops peptides for neuroinflammatory diseases with a focus on Alzheimer's disease and related dementias.

The pipeline comprises 15 named peptide drug candidates spanning autoimmune (KINE-101A rheumatoid arthritis, KINE-101B IBD, KINE-101C CIDP, KINE-101D NASH), dermatology and respiratory (KINE-201A atopic dermatitis, KINE-201B asthma, KINE-201C COPD, KINE-301A psoriasis), oncology (KINE-401A solid tumor), CNS (KINE-501A Alzheimer's, KINE-501B FTD, KINE-501C LBD, KINE-501D Parkinson's), and other indications (KINE-601A wound healing, KINE-601B alopecia). The most advanced asset, KINE-101 for CIDP, entered Phase 1b/2a clinical trials in September 2024 after Phase 1 approval in July 2024.

Kine Sciences is pre-revenue and derives no current commercial income. Revenue model is effectively grant-equity funded, with approximately 26 billion KRW raised cumulatively since 2019 through convertible preferred and common share issuances. The company has no third-party distribution or commercial partnerships; all pipeline assets are advanced internally through clinical trials managed by its R&D divisions. As of September 2024, Kine Sciences has appointed Dongsung Accounting Corporation as external auditor in preparation for a Korean stock exchange listing (상장예정).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, autoimmune disease drugs, neuroinflammatory treatments, clinical stage biotech, regulatory T-cell peptides
Industry5 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAF
Multiple Sclerosis & Neuroimmunology
SECONDARYHLAKAIAC
Movement Disorders (Parkinson’s, Tremor, Dystonia)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Peptide Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-Revenue / Clinical Stage
TypeSubscription Recurring
Description

Kine Sciences is a pre-revenue clinical-stage biopharmaceutical company. All drug candidates are in preclinical or clinical development phases. No commercialized products or revenue streams are currently disclosed.

kinesciences.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kine Sciences is a clinical-stage biopharmaceutical company developing ultra-peptide drug candidates to treat chronic immune and neuroinflammatory diseases. Through its Immune Disease Division and Neurological Disease Division (Central Research Institute, CRI), it advances a pipeline of peptide therapeutics targeting regulatory T-cells, Th2, Th17, and NK cell pathways for autoimmune, dermatological, respiratory, metabolic, oncologic, and CNS indications. Its most advanced candidate, KINE-101, is in a Phase 1b/2a clinical trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First patient dosed in Phase 1b/2a clinical trial of KINE-101 for CIDP
Product overview1 text field

Kine Sciences is a biotech company developing peptide-based therapeutics through two main R&D divisions: the Immune Disease Division (focusing on autoimmune, inflammatory, dermatological, respiratory, and metabolic diseases) and the Neurological Disease Division (focusing on neuroinflammatory diseases including Alzheimer's and other dementias). The company's pipeline includes multiple drug candidates across therapeutic areas: KINE-101 series (autoimmune/metabolic: RA, IBD, CIDP, NASH), KINE-201 series (inflammatory skin and respiratory: atopic dermatitis, asthma, COPD), KINE-301 (psoriasis), KINE-401 (solid tumors), KINE-501 series (CNS/neurodegenerative: Alzheimer's, FTD, LBD, Parkinson's), and KINE-601 series (wound healing, alopecia). The most advanced candidate KINE-101 for CIDP is in Phase 1b/2a clinical trials.

Product and service15 records
1KINE-101A
CategoryAutoimmune Peptide Drug Candidate
2KINE-101B
CategoryAutoimmune Peptide Drug Candidate
3KINE-101C (KINE-101)
CategoryNeurological / Autoimmune Peptide Drug Candidate
4KINE-101D
CategoryMetabolic Peptide Drug Candidate
5KINE-201A
CategoryDermatology Peptide Drug Candidate
6KINE-201B
CategoryRespiratory Peptide Drug Candidate
7KINE-201C
CategoryRespiratory Peptide Drug Candidate
8KINE-301A
CategoryDermatology Peptide Drug Candidate
9KINE-401A
CategoryOncology Peptide Drug Candidate
10KINE-501A
CategoryNeurodegenerative Peptide Drug Candidate
11KINE-501B
CategoryNeurodegenerative Peptide Drug Candidate
12KINE-501C
CategoryNeurodegenerative Peptide Drug Candidate
13KINE-501D
CategoryNeurodegenerative Peptide Drug Candidate
14KINE-601A
CategoryRegenerative Peptide Drug Candidate
15KINE-601B
CategoryRegenerative Peptide Drug Candidate
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthersAnnounced on2024-06-26
Description

Song Sang-yong (송상용), formerly of Samsung Medical Center, was recruited as Head of Business Operations at Kine Sciences. This is a talent acquisition rather than a formal institutional partnership.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Denali Therapeutics is a well-funded CNS biotech developing therapies for neurodegeneration including Parkinson's and Alzheimer's. Overlaps with Kine Sciences' KINE-501 series, though at much later stage of development and broader modality coverage.

TypeDirect peer
Description

Zealand Pharma specializes in peptide-based therapeutics, including stable, modified peptides for metabolic and specialty indications. Directly comparable as a peptide-platform biotech advancing multiple programs through clinical development.

TypeEmerging player
Description

Alector is a clinical-stage biotech developing immuno-neurology treatments for neurodegenerative diseases. Overlaps with Kine Sciences' CNS neuroinflammatory pipeline (Alzheimer's, FTD), though using antibody approaches rather than peptides.

TypeDirect peer
Description

Argenx is a leading immunology biotech with an approved drug (Vyvgart) for CIDP. Direct overlap with Kine Sciences' lead CIDP indication (KINE-101) makes it the closest functional peer.

TypeRegional player
Description

Helixmith is a Korean clinical-stage biotech advancing gene therapy and biologics for neurological and rare diseases. Regional peer based in Seoul, similarly focused on autoimmune/neuro indications and pursuing clinical-stage Korean biotech dynamics.

TypeDirect peer
Description

Protagonist Therapeutics develops proprietary peptide therapeutics for diseases including autoimmune (e.g., JAK inhibitor peptides and hematology). Comparable as a peptide-platform biotech pursuing inflammatory and rare disease indications.

TypeDirect peer
Description

Bicycle Therapeutics develops bicyclic peptide-based therapeutics with a proprietary discovery platform. Highly comparable on core technology — engineered peptides for targeted disease modulation — though focused on oncology rather than autoimmune/CNS.

8PeptiDream
TypeDirect peer
Description

PeptiDream operates a proprietary non-standard peptide discovery platform (PDPS) used widely through pharma collaborations. Closest technology analogue to Kine Sciences' peptide discovery platform with licensing model dynamics.

TypeBroad incumbent
Description

Celltrion is a major Korean biopharmaceutical company developing biosimilars and novel biologics including autoimmune therapeutics. Korea-based incumbent in autoimmune biologics that dwarfs Kine Sciences' scale but competes for the same domestic ecosystem and talent pool.

TypeRegional player
Description

Genexine is a Korean biotech developing biopharmaceuticals including immuno-oncology and autoimmune candidates with multiple clinical assets. Regional comparable — Korean biotech ecosystem peer with similar clinical-stage profile and pipeline breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kine Sciences

Biopharmaceutical Peptide Therapeuticskinesciences.com

What Kine Sciences does

Kine Sciences (카인사이언스) is a clinical-stage Korean biopharmaceutical company headquartered in Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea, that develops ultra-peptide medicines targeting chronic immune and neuroinflammatory diseases. The company operates two R&D divisions: the Immune Disease Division, which develops regulatory T-cell (Treg) activating peptides that restore immune homeostasis by modulating Treg, Th2, Th17, and NK cell activity, and the Central Research Institute (CRI), which develops peptides for neuroinflammatory diseases with a focus on Alzheimer's disease and related dementias.

The pipeline comprises 15 named peptide drug candidates spanning autoimmune (KINE-101A rheumatoid arthritis, KINE-101B IBD, KINE-101C CIDP, KINE-101D NASH), dermatology and respiratory (KINE-201A atopic dermatitis, KINE-201B asthma, KINE-201C COPD, KINE-301A psoriasis), oncology (KINE-401A solid tumor), CNS (KINE-501A Alzheimer's, KINE-501B FTD, KINE-501C LBD, KINE-501D Parkinson's), and other indications (KINE-601A wound healing, KINE-601B alopecia). The most advanced asset, KINE-101 for CIDP, entered Phase 1b/2a clinical trials in September 2024 after Phase 1 approval in July 2024.

Kine Sciences is pre-revenue and derives no current commercial income. Revenue model is effectively grant-equity funded, with approximately 26 billion KRW raised cumulatively since 2019 through convertible preferred and common share issuances. The company has no third-party distribution or commercial partnerships; all pipeline assets are advanced internally through clinical trials managed by its R&D divisions. As of September 2024, Kine Sciences has appointed Dongsung Accounting Corporation as external auditor in preparation for a Korean stock exchange listing (상장예정).

Kine Sciences firmographics

Firmographics
Name
Kine Sciences
Legal name
주식회사 카인사이언스 (Kine Sciences Co., Ltd.)
Website
https://kinesciences.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Kine Sciences industry classification

Industry
Product category
Biopharmaceutical Peptide Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAF
Multiple Sclerosis & Neuroimmunology
SECONDARYHLAKAIAC
Movement Disorders (Parkinson’s, Tremor, Dystonia)

Keywords

  • Peptide therapeutics
  • Autoimmune disease drugs
  • Neuroinflammatory treatments
  • Clinical stage biotech
  • Regulatory T-cell peptides

Where Kine Sciences is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Kine Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pre-Revenue / Clinical Stage: Kine Sciences is a pre-revenue clinical-stage biopharmaceutical company. All drug candidates are in preclinical or clinical development phases. No commercialized products or revenue streams are currently disclosed.

Go-to-market motion1 record

Marketing channels2 records

Kine Sciences product offering

Product offering

Core offering

Kine Sciences is a clinical-stage biopharmaceutical company developing ultra-peptide drug candidates to treat chronic immune and neuroinflammatory diseases. Through its Immune Disease Division and Neurological Disease Division (Central Research Institute, CRI), it advances a pipeline of peptide therapeutics targeting regulatory T-cells, Th2, Th17, and NK cell pathways for autoimmune, dermatological, respiratory, metabolic, oncologic, and CNS indications. Its most advanced candidate, KINE-101, is in a Phase 1b/2a clinical trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Product overview

Kine Sciences is a biotech company developing peptide-based therapeutics through two main R&D divisions: the Immune Disease Division (focusing on autoimmune, inflammatory, dermatological, respiratory, and metabolic diseases) and the Neurological Disease Division (focusing on neuroinflammatory diseases including Alzheimer's and other dementias). The company's pipeline includes multiple drug candidates across therapeutic areas: KINE-101 series (autoimmune/metabolic: RA, IBD, CIDP, NASH), KINE-201 series (inflammatory skin and respiratory: atopic dermatitis, asthma, COPD), KINE-301 (psoriasis), KINE-401 (solid tumors), KINE-501 series (CNS/neurodegenerative: Alzheimer's, FTD, LBD, Parkinson's), and KINE-601 series (wound healing, alopecia). The most advanced candidate KINE-101 for CIDP is in Phase 1b/2a clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • KINE-101A
  • KINE-101B
  • KINE-101C (KINE-101)
  • KINE-101D
  • KINE-201A
  • KINE-201B
  • KINE-201C
  • KINE-301A
  • KINE-401A
  • KINE-501A
  • KINE-501B
  • KINE-501C
  • KINE-501D
  • KINE-601A
  • KINE-601B

Quantifiable outcome

  • First patient dosed in Phase 1b/2a clinical trial of KINE-101 for CIDP

Companies that use Kine Sciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Kine Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Kine Sciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Samsung Medical Center (삼성서울병원)minorOthers · 26 June 2024Song Sang-yong (송상용), formerly of Samsung Medical Center, was recruited as Head of Business Operations at Kine Sciences. This is a talent acquisition rather than a formal institutional partnership.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Kine Sciences competitors and assessment

Company assessment

Broad incumbents

  • Denali Therapeutics: Denali Therapeutics is a well-funded CNS biotech developing therapies for neurodegeneration including Parkinson's and Alzheimer's. Overlaps with Kine Sciences' KINE-501 series, though at much later stage of development and broader modality coverage.
  • Celltrion: Celltrion is a major Korean biopharmaceutical company developing biosimilars and novel biologics including autoimmune therapeutics. Korea-based incumbent in autoimmune biologics that dwarfs Kine Sciences' scale but competes for the same domestic ecosystem and talent pool.

Direct peers

  • Zealand Pharma: Zealand Pharma specializes in peptide-based therapeutics, including stable, modified peptides for metabolic and specialty indications. Directly comparable as a peptide-platform biotech advancing multiple programs through clinical development.
  • Argenx: Argenx is a leading immunology biotech with an approved drug (Vyvgart) for CIDP. Direct overlap with Kine Sciences' lead CIDP indication (KINE-101) makes it the closest functional peer.
  • Protagonist Therapeutics: Protagonist Therapeutics develops proprietary peptide therapeutics for diseases including autoimmune (e.g., JAK inhibitor peptides and hematology). Comparable as a peptide-platform biotech pursuing inflammatory and rare disease indications.
  • Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide-based therapeutics with a proprietary discovery platform. Highly comparable on core technology — engineered peptides for targeted disease modulation — though focused on oncology rather than autoimmune/CNS.
  • PeptiDream: PeptiDream operates a proprietary non-standard peptide discovery platform (PDPS) used widely through pharma collaborations. Closest technology analogue to Kine Sciences' peptide discovery platform with licensing model dynamics.

Emerging players

  • Alector: Alector is a clinical-stage biotech developing immuno-neurology treatments for neurodegenerative diseases. Overlaps with Kine Sciences' CNS neuroinflammatory pipeline (Alzheimer's, FTD), though using antibody approaches rather than peptides.

Regional players

  • Helixmith: Helixmith is a Korean clinical-stage biotech advancing gene therapy and biologics for neurological and rare diseases. Regional peer based in Seoul, similarly focused on autoimmune/neuro indications and pursuing clinical-stage Korean biotech dynamics.
  • Genexine: Genexine is a Korean biotech developing biopharmaceuticals including immuno-oncology and autoimmune candidates with multiple clinical assets. Regional comparable — Korean biotech ecosystem peer with similar clinical-stage profile and pipeline breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Kine Sciences social profiles

Digital presence

Kine Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kine Sciences leadership team

Management profile

Number of profiles

Profiles9 records

Kine Sciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kine Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kine Sciences

What does Kine Sciences do?

Kine Sciences is a clinical-stage biopharmaceutical company developing ultra-peptide drug candidates to treat chronic immune and neuroinflammatory diseases. Through its Immune Disease Division and Neurological Disease Division (Central Research Institute, CRI), it advances a pipeline of peptide therapeutics targeting regulatory T-cells, Th2, Th17, and NK cell pathways for autoimmune, dermatological, respiratory, metabolic, oncologic, and CNS indications. Its most advanced candidate, KINE-101, is in a Phase 1b/2a clinical trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Is Kine Sciences a public or private company?

Kine Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kine Sciences founded?

Kine Sciences was founded in 2019. It employs 11 to 50 people.

Where is Kine Sciences based?

Kine Sciences is headquartered in Seoul, South Korea, in the Asia region.

How does Kine Sciences make money?

One revenue line is on record: pre-Revenue / Clinical Stage.

Who are Kine Sciences's main competitors?

Broad incumbents on record are Denali Therapeutics and Celltrion. Direct peers are Zealand Pharma, Argenx, Protagonist Therapeutics, Bicycle Therapeutics and PeptiDream. Alector is listed as an emerging player. Regional players are Helixmith and Genexine.

Does Kine Sciences have an API?

No public API is recorded for Kine Sciences.

What industry is Kine Sciences in?

Kine Sciences's product category is Biopharmaceutical Peptide Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales